These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

751 related articles for article (PubMed ID: 35188552)

  • 21. Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial.
    Suntharalingam M; Winter K; Ilson D; Dicker AP; Kachnic L; Konski A; Chakravarthy AB; Anker CJ; Thakrar H; Horiba N; Dubey A; Greenberger JS; Raben A; Giguere J; Roof K; Videtic G; Pollock J; Safran H; Crane CH
    JAMA Oncol; 2017 Nov; 3(11):1520-1528. PubMed ID: 28687830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial.
    Jiang H; Makelike K; Chen B; Xi M; Li Q; Hu Y; Zhu Y
    Radiat Oncol; 2023 Sep; 18(1):150. PubMed ID: 37700348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The significance of consolidation chemotherapy after concurrent chemoradiotherapy in esophageal squamous cell carcinoma: a randomized controlled phase III clinical trial.
    Zhu Q; Zhang C; Li Z; Ma T; Wang N; Liu W; He Z; Shen J; Wei T; Zhao S; Feng L; Tian Y
    Thorac Cancer; 2024 Oct; 15(28):2038-2048. PubMed ID: 39199003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903).
    Sun HB; Xing WQ; Liu XB; Zheng Y; Yang SJ; Wang ZF; Liu SL; Ba YF; Zhang RX; Liu BX; Fan CC; Chen PN; Liang GH; Yu YK; Liu Q; Wang HR; Li HM; Li ZX;
    BMC Cancer; 2020 Apr; 20(1):303. PubMed ID: 32293362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
    Conroy T; Galais MP; Raoul JL; Bouché O; Gourgou-Bourgade S; Douillard JY; Etienne PL; Boige V; Martel-Lafay I; Michel P; Llacer-Moscardo C; François E; Créhange G; Abdelghani MB; Juzyna B; Bedenne L; Adenis A;
    Lancet Oncol; 2014 Mar; 15(3):305-14. PubMed ID: 24556041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study.
    Jiang L; Zhu J; Chen X; Wang Y; Wu L; Wan G; Han Y; Leng X; Peng L; Wang Q
    Radiat Oncol; 2022 Dec; 17(1):218. PubMed ID: 36585731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II study of concurrent chemoradiotherapy combined with a weekly paclitaxel and 5-fluorouracil regimen to treat patients with advanced oesophageal carcinoma.
    Xia Y; Li YH; Chen Y; Zhang JH; Liu Q; Deng JY; Ai TS; Zhu HT; Fan JH; Badakhshi H; Zhao KL
    Radiat Oncol; 2017 Mar; 12(1):47. PubMed ID: 28270162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial.
    Kato K; Machida R; Ito Y; Daiko H; Ozawa S; Ogata T; Hara H; Kojima T; Abe T; Bamba T; Watanabe M; Kawakubo H; Shibuya Y; Tsubosa Y; Takegawa N; Kajiwara T; Baba H; Ueno M; Takeuchi H; Nakamura K; Kitagawa Y;
    Lancet; 2024 Jul; 404(10447):55-66. PubMed ID: 38876133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: a phase II clinical trial.
    Wang Z; Hu M; Hu Y; Li Q; Wu J; Fong WP; Ren C; Wang D; Tan Q; Yang H; Li Y
    Esophagus; 2022 Jan; 19(1):120-128. PubMed ID: 34319435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial.
    McCormack M; Eminowicz G; Gallardo D; Diez P; Farrelly L; Kent C; Hudson E; Panades M; Mathew T; Anand A; Persic M; Forrest J; Bhana R; Reed N; Drake A; Adusumalli M; Mukhopadhyay A; King M; Whitmarsh K; McGrane J; Colombo N; Mak C; Mandal R; Chowdhury RR; Alamilla-Garcia G; Chávez-Blanco A; Stobart H; Feeney A; Vaja S; Hacker AM; Hackshaw A; Ledermann JA;
    Lancet; 2024 Oct; 404(10462):1525-1535. PubMed ID: 39419054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
    Nomura H; Aoki D; Michimae H; Mizuno M; Nakai H; Arai M; Sasagawa M; Ushijima K; Sugiyama T; Saito M; Tokunaga H; Matoda M; Nakanishi T; Watanabe Y; Takahashi F; Saito T; Yaegashi N;
    JAMA Oncol; 2019 Jun; 5(6):833-840. PubMed ID: 30896757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma.
    Zeng J; Cui X; Cheng L; Chen Y; Du X; Sheng L
    Cancer Radiother; 2021 Jul; 25(5):441-446. PubMed ID: 33958272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial.
    Xie C; Jing Z; Luo H; Jiang W; Ma L; Hu W; Zheng A; Li D; Ding L; Zhang H; Xie C; Lian X; Du D; Chen M; Bian X; Tan B; Xia B; Xie R; Liu Q; Wang L; Wu S
    Br J Cancer; 2020 Nov; 123(11):1616-1624. PubMed ID: 32958820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
    Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
    Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma.
    Zhou XL; Yu CH; Wang WW; Ji FZ; Xiong YZ; Zhu WG; Tong YS
    Radiat Oncol; 2021 May; 16(1):94. PubMed ID: 34039375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tolerability and efficacy of concurrent chemoradiotherapy comparing carboplatin/paclitaxel versus platinum/5-FU regimen for locally advanced esophageal and esophagogastric junction cancers.
    Tamtai A; Jiarpinitnun C; Hiranyatheb P; Unwanatham N; Sirachainun E; Supsamutchai C; Pattaranutaporn P; Ngamphaiboon N
    Med Oncol; 2017 Sep; 34(9):157. PubMed ID: 28785986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
    Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
    Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer.
    Jiang DM; Sim HW; Espin-Garcia O; Chan BA; Natori A; Lim CH; Moignard S; Chen EX; Liu G; Darling G; Swallow CJ; Brar S; Brierley J; Ringash J; Wong R; Kim J; Rogalla P; Hafezi-Bakhtiari S; Knox JJ; Jang RW; Elimova E
    Oncology; 2021; 99(1):49-56. PubMed ID: 33053548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial.
    Zhu Y; Wen J; Li Q; Chen B; Zhao L; Liu S; Yang Y; Wang S; Lv Y; Li J; Zhang L; Hu Y; Liu M; Xi M
    Lancet Oncol; 2023 Apr; 24(4):371-382. PubMed ID: 36990609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.